

IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

7 March 2023

Correction to Announcement and Offer Booklet

MELBOURNE – Imagion Biosystems (**ASX:IBX, Imagion or the Company**), refers to its announcement of today, titled 'Imagion Secures Growth Funding' (**Announcement**) and 'Entitlement Offer Offer Booklet' released to ASX today (**Offer Booklet**).

1. Announcement

The Company notes that in the third dot point under the heading "Other key terms" in the Announcement, the following words are deleted:

"26,138,956 of these options will be issued under the Company's 7.1 capacity, with the remainder being subject to shareholder approval."

and replaced with the following:

"14,138,956 of these options will be issued under the Company's 7.1 capacity, with the remainder being subject to shareholder approval."

2. Offer Booklet

The Company notes that in the note to the table in section 3.1 of the Offer Booklet, the following words are deleted:

"Subject to certain conditions being satisfied, under Mercer's first tranche investment, 22,058,824 Shares, 26,138,956 unlisted options and convertible securities with an aggregate face value of \$1,650,000 may be issued to Mercer within 10 business days of 7 March 2023 (with a further 15,995,876 unlisted options which may be issued upon receiving shareholder approval)."

and replaced with:

"Subject to certain conditions being satisfied, under Mercer's first tranche investment, 22,058,824 Shares, 14,138,956 unlisted options and convertible securities with an aggregate face value of \$1,650,000 may be issued to Mercer within 10 business days of 7 March 2023 (with a further 27,995,876 unlisted options which may be issued upon receiving shareholder approval)."

-ENDS

**About Imagion Biosystems**

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Company Secretary of Imagion Biosystems Limited

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 450648064